There is a growing body of evidence behind injectable weight loss treatments, but with several options now available, knowing which one to choose can feel confusing. For patients in Newport who have been researching their options, this guide focuses specifically on Wegovy: how it compares to other treatments, what the clinical evidence actually shows, and why the right choice ultimately comes down to your individual health profile rather than which medication has the most attention.
Making an informed decision before your first consultation puts you in the best possible position to get the most from treatment from day one.
To speak with our team and find out which treatment may be right for you, contact us at info@mayberrypharmacy.co.uk or book a consultation online today.
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone involved in appetite regulation and blood sugar control. It reduces hunger, slows gastric emptying, and helps patients feel fuller for longer. It is administered once weekly via a pre-filled injection pen and is licensed in the UK for weight management alongside diet and physical activity.
According to the NHS, Wegovy is a prescription-only medicine for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. It should be used under medical supervision as part of a structured weight management programme.
Wegovy differs from older treatments by targeting appetite-regulating hormones and has been studied extensively in large clinical trials demonstrating significant weight loss.

The STEP clinical trial programme provided the data behind Wegovy’s approval. The key findings are summarised below:
| Trial | Population | Duration | Average Weight Loss (Wegovy) |
|---|---|---|---|
| STEP 1 | Adults with obesity, no type 2 diabetes | 68 weeks | ~14.9% |
| STEP 2 | Adults with obesity and type 2 diabetes | 68 weeks | ~9.6% |
| STEP 3 | Adults with obesity plus intensive behavioural therapy | 68 weeks | ~16% |
| STEP 4 | Adults who continued vs stopped treatment after 20 weeks | 48 weeks | Continued: further ~7.9% vs regain of ~6.9% in placebo group |
These figures represent averages from large trial populations. Individual results will always vary based on starting weight, lifestyle factors, and how consistently treatment is maintained.
Patients without type 2 diabetes tend to achieve stronger average weight loss on Wegovy than those with the condition, as the STEP trial data shows. Your broader health profile, including any medications you take, will be assessed during your consultation to give you the most accurate picture of what to expect.
The STEP 3 trial, which combined Wegovy with intensive behavioural therapy, achieved the highest average weight loss of the series at around 16%. This underlines how significantly diet, activity, and behavioural support can amplify the medication’s effects.
The STEP 4 trial demonstrated clearly that stopping Wegovy after an initial period of success leads to significant weight regain. Patients who continued treatment maintained and extended their results, highlighting the importance of long-term commitment to the programme.
Patients who are able to progress through the full dose escalation schedule and maintain the 2.4 mg maintenance dose tend to achieve stronger results. The gradual dose increase is designed to support tolerability, and your prescriber will guide you through each step.
If you are also weighing up Wegovy against Mounjaro, our detailed comparison of Mounjaro vs Wegovy breaks down the clinical differences between the two treatments to help you have a more informed conversation at your consultation. For patients who have already tried one treatment and are considering switching, our guide on switching from Mounjaro to Wegovy covers what the transition involves.
Before any prescription is issued, a thorough consultation is carried out to confirm suitability. Wegovy may be appropriate for adults who:

Yes. Our Newport branch offers private Wegovy consultations and prescriptions. Online booking is available for your convenience.
Both Wegovy and Ozempic contain semaglutide, but they are different licensed products. Ozempic is licensed for blood sugar management in type 2 diabetes, while Wegovy is licensed specifically for chronic weight management. The doses also differ, with Wegovy reaching a higher maintenance dose of 2.4 mg.
No referral is needed. You can book directly with our team and we will carry out a full suitability assessment before any prescription is issued.
Many patients notice appetite changes within the first two to four weeks. Visible weight loss typically becomes more apparent from weeks four to eight, with the most significant cumulative results developing over several months of consistent treatment at the maintenance dose.
Wegovy contains semaglutide and acts on one hormone pathway (GLP-1), while Mounjaro contains tirzepatide and acts on two pathways (GIP and GLP-1). Both are effective licensed treatments, but they work differently and suit different patient profiles. Our team can help you understand which may be more appropriate for you during a consultation.
Choosing the right weight loss treatment is a significant decision, and having access to clear, evidence-based information makes that decision much easier. At Mayberry Pharmacy, our team provides honest guidance, thorough clinical assessments, and ongoing support throughout your treatment journey.
We serve patients across South Wales from our branches in Newport, Caerphilly, Blackwood, Crumlin, Pontypool, Trevethin, and Penarth.
Get in touch at info@mayberrypharmacy.co.uk or book your weight loss consultation online today.